Business Standard

Tuesday, December 24, 2024 | 02:46 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

S&P, Nasdaq higher on Covid-19 vaccine hopes, improving economic data

A Covid-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials

wall street
Premium

On Thursday, all eyes will be on the Labor Department's nonfarm payrolls report

Pawel Goraj and Devik Jain | Reuters
The S&P 500 and Nasdaq rose on Wednesday as rising hopes of a Covid-19 vaccine offset fears of another round of lockdowns following a record surge in coronavirus cases in the United States.
 
A Covid-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trial, the companies said.
 
Pfizer's shares rose 4.8% on the news, one of the biggest boost to the S&P 500 index, while BioNTech gained 3%, helping improve the mood on Wall Street after the United States registered 47,000 new coronavirus cases on Tuesday,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in